RedHill Biopharma (NASDAQ:RDHL) Stock Passes Below 200 Day Moving Average of $1.38

RedHill Biopharma Ltd. (NASDAQ:RDHLGet Rating)’s share price passed below its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of $1.38 and traded as low as $0.85. RedHill Biopharma shares last traded at $0.89, with a volume of 393,337 shares.

RedHill Biopharma Price Performance

The company has a debt-to-equity ratio of 9.42, a current ratio of 0.98 and a quick ratio of 0.79. The stock has a market capitalization of $46.82 million, a P/E ratio of -0.47 and a beta of 1.80. The company’s 50 day simple moving average is $0.94 and its two-hundred day simple moving average is $1.38.

RedHill Biopharma (NASDAQ:RDHLGet Rating) last released its quarterly earnings results on Thursday, June 23rd. The biotechnology company reported ($0.30) EPS for the quarter, beating the consensus estimate of ($0.40) by $0.10. RedHill Biopharma had a negative net margin of 110.31% and a negative return on equity of 822.29%. The business had revenue of $18.24 million for the quarter. During the same period last year, the company earned ($0.53) earnings per share. As a group, equities analysts expect that RedHill Biopharma Ltd. will post -0.83 EPS for the current fiscal year.

Institutional Investors Weigh In On RedHill Biopharma

A number of hedge funds and other institutional investors have recently made changes to their positions in RDHL. Disciplined Growth Investors Inc. MN increased its stake in RedHill Biopharma by 0.7% in the 1st quarter. Disciplined Growth Investors Inc. MN now owns 1,950,002 shares of the biotechnology company’s stock valued at $4,914,000 after buying an additional 14,413 shares during the last quarter. ARK Investment Management LLC grew its position in shares of RedHill Biopharma by 21.3% in the 2nd quarter. ARK Investment Management LLC now owns 1,045,023 shares of the biotechnology company’s stock valued at $1,170,000 after acquiring an additional 183,225 shares during the period. Millennium Management LLC bought a new position in shares of RedHill Biopharma in the 2nd quarter valued at about $324,000. Gagnon Securities LLC boosted its holdings in shares of RedHill Biopharma by 15.4% during the 1st quarter. Gagnon Securities LLC now owns 367,346 shares of the biotechnology company’s stock worth $926,000 after buying an additional 49,023 shares during the period. Finally, BlackRock Inc. boosted its holdings in shares of RedHill Biopharma by 18.6% during the 1st quarter. BlackRock Inc. now owns 357,493 shares of the biotechnology company’s stock worth $901,000 after buying an additional 56,178 shares during the period. 7.74% of the stock is currently owned by institutional investors and hedge funds.

RedHill Biopharma Company Profile

(Get Rating)

RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with chronic non-cancer pain; Talicia for the treatment of Helicobacter pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults.

Further Reading

Receive News & Ratings for RedHill Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RedHill Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.